|
KR20210006356A
(ko)
|
2018-04-04 |
2021-01-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해 조절제 및 연관된 사용 방법
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
KR20240163107A
(ko)
|
2022-03-11 |
2024-11-18 |
컴쿼트 바이오사이언시즈 인크. |
헤테로환 화합물 및 이의 용도
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CA3261681A1
(en)
|
2022-08-05 |
2024-02-08 |
Kumquat Biosciences Inc. |
HETEROCYCLIC COMPOUNDS AND THEIR USES
|
|
AU2023320914A1
(en)
*
|
2022-08-11 |
2025-02-27 |
Beone Medicines I Gmbh |
Heterocyclic compounds, compositions thereof, and methods of treatment therewith
|
|
WO2024041573A1
(en)
*
|
2022-08-25 |
2024-02-29 |
Zai Lab (Shanghai) Co., Ltd. |
Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
|
|
JP2025535294A
(ja)
*
|
2022-10-18 |
2025-10-24 |
アイディーエンス カンパニー リミテッド |
新規なトリヘテロ環化合物
|
|
JP2025535367A
(ja)
*
|
2022-10-19 |
2025-10-24 |
ジェネンテック， インコーポレイテッド |
６－アザ部分を含むオキサゼピン化合物およびその使用
|
|
WO2024112654A1
(en)
|
2022-11-21 |
2024-05-30 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2024153180A1
(zh)
*
|
2023-01-18 |
2024-07-25 |
上海艾力斯医药科技股份有限公司 |
杂环类化合物、其药物组合物及其用途
|
|
CN121419983A
(zh)
|
2023-01-26 |
2026-01-27 |
阿尔维纳斯运营股份有限公司 |
基于小脑蛋白的kras降解protac及其相关用途
|
|
WO2024197503A1
(en)
*
|
2023-03-27 |
2024-10-03 |
Nikang Therapeutics , Inc. |
Tricyclic derivatives as kras inhibitors
|
|
EP4687905A1
(en)
|
2023-03-30 |
2026-02-11 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
KR20260005904A
(ko)
|
2023-04-07 |
2026-01-12 |
레볼루션 메디슨즈, 인크. |
매크로사이클릭 ras 억제제
|
|
CN121263418A
(zh)
|
2023-04-07 |
2026-01-02 |
锐新医药公司 |
大环ras抑制剂
|
|
KR20250172857A
(ko)
|
2023-04-14 |
2025-12-09 |
레볼루션 메디슨즈, 인크. |
Ras 억제제의 결정형
|
|
AU2024252105A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
EP4713330A1
(en)
*
|
2023-05-16 |
2026-03-25 |
HUTCHMED Limited |
Tricyclic compounds and uses thereof
|
|
CN121605110A
(zh)
*
|
2023-06-06 |
2026-03-03 |
金橘生物科技公司 |
取代杂环化合物及其用途
|
|
AU2024307234A1
(en)
*
|
2023-06-30 |
2026-01-29 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
CN116903499B
(zh)
*
|
2023-07-11 |
2025-05-30 |
上海应用技术大学 |
无水氟磺酰基二氟乙酸铜盐及其制备方法与应用
|
|
IL326136A
(en)
|
2023-08-07 |
2026-03-01 |
Revolution Medicines Inc |
RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
|
|
AU2024323424A1
(en)
|
2023-08-17 |
2026-03-05 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
TW202528315A
(zh)
|
2023-09-21 |
2025-07-16 |
美商樹線生物科學公司 |
螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250163079A1
(en)
*
|
2023-11-01 |
2025-05-22 |
Incyte Corporation |
Kras inhibitors
|
|
WO2025111586A1
(en)
|
2023-11-22 |
2025-05-30 |
Genentech, Inc. |
Polymorphs of and synthetic process for an aza-tetracyclic oxazepine inhibitor of kras-g12d
|
|
TW202527946A
(zh)
*
|
2023-12-19 |
2025-07-16 |
大陸商正大天晴藥業集團股份有限公司 |
三并環類化合物及其醫藥用途
|
|
WO2025167948A1
(zh)
*
|
2024-02-06 |
2025-08-14 |
上海齐鲁制药研究中心有限公司 |
嘧啶并大环类kras抑制剂
|
|
WO2025168072A1
(en)
*
|
2024-02-08 |
2025-08-14 |
Beigene (Suzhou) Co., Ltd. |
Heterocyclic compounds, compositions thereof, and methods of treatment therewith
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|